Workflow
Lineage Cell Therapeutics(LCTX)
icon
Search documents
Lineage Cell Therapeutics(LCTX) - 2021 Q1 - Earnings Call Transcript
2021-05-14 01:23
Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Ioana Hone - Director of Investor Relations Brian Culley - Chief Executive Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Joe Pantginis - H.C. Wainwright Robert LeBoyer - Noble Capital Keay Nakae - Chardan Operator Welcome to the Lineage Cell Therapeutics’ First Quarter 2021 Conference Call. At this time, all participants are in a listen only mode. An audio webca ...
Lineage Cell Therapeutics(LCTX) - 2021 Q1 - Quarterly Report
2021-05-13 20:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (Stat ...
Lineage Cell Therapeutics(LCTX) - 2020 Q4 - Earnings Call Transcript
2021-03-12 01:27
Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q4 2020 Earnings Conference Call March 11, 2021 4:30 PM ET Company Participants Ioana Hone – Director-Investor Relations Brian Culley – Chief Executive Officer Brandi Roberts – Chief Financial Officer Conference Call Participants Joe Pantginis – H.C. Wainwright Jason McCarthy – Maxim Group Keay Nakae – Chardan Operator Ladies and gentlemen welcome to the Lineage Cell Therapeutics' Fourth Quarter and Year End 2020 Conference Call. At this time, all participants are ...
Lineage Cell Therapeutics(LCTX) - 2020 Q4 - Annual Report
2021-03-11 21:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...
Lineage Cell Therapeutics (LCTX) Investor Presentation - Slideshow
2021-01-20 21:12
The future of cell therapy. Corporate Overview January 6, 2021 Forward-Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Lineage Cell Therapeutics, Inc. ("Lineage"). This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Lineage has not independently verified such information and there can be no assurance as to its accurac ...
Lineage Cell Therapeutics(LCTX) - 2020 Q3 - Earnings Call Transcript
2020-11-05 04:08
Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q3 2020 Results Earnings Conference Call November 4, 2020 4:30 PM ET Company Participants Ioana Hone - Director, Investor Relations Brian Culley - Chief Executive Officer Brandi Roberts - Chief Financial Officer Conference Call Participants Jason McCarthy - Maxim Group LLC Joseph Pantginis - H.C. Wainwright & Co., LLC Ahu Demir - Noble Life Science Partners Keay Nakae - Chardan Capital Markets Operator Welcome to the Lineage Cell Therapeutics Third Quarter 2020 Co ...
Lineage Cell Therapeutics(LCTX) - 2020 Q3 - Quarterly Report
2020-11-04 21:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. 2173 Salk Avenue, Suite 200 Carlsbad, California 92008 (Address of principal e ...
Lineage Cell Therapeutics (LCTX) Investor Presentation - Slideshow
2020-09-17 18:30
The future of cell therapy. Corporate Overview Brian M. Culley, Chief Executive Officer September 14, 2020 Forward-Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Lineage Cell Therapeutics, Inc. ("Lineage"). This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Lineage has not independently verified such information and ...
Lineage Cell Therapeutics (LCTX) Presents At LD Micro 500 Virtual Investor Conference - Slideshow
2020-09-01 21:24
The future of cell therapy. LD Micro 500 Virtual Investor Conference Brian M. Culley, Chief Executive Officer September 1, 2020 Forward-Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Lineage Cell Therapeutics, Inc. ("Lineage"). This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Lineage has not independently verified ...
Lineage Cell Therapeutics(LCTX) - 2020 Q2 - Earnings Call Transcript
2020-08-07 02:38
Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q2 2020 Earnings Conference Call August 6, 2020 5:30 PM ET Corporate Participants Ioana Hone - Director, Investor Relations Brian Culley - Chief Executive Officer Brandi Roberts - Chief Financial Officer Gary Hogge - Senior Vice President, Clinical and Medical Affairs Conference Call participants Joe Pantginis - H.C. Wainwright Dane Leone - Raymond James Operator Welcome to the Lineage Cell Therapeutics Second Quarter 2020 Conference Call. At this time, all partic ...